The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).
 
Christian Fottner
Honoraria - Novartis/Ipsen
Consulting or Advisory Role - Novartis/Ipsen
Travel, Accommodations, Expenses - Novartis/Ipsen
 
Leonidas Apostolidis
Honoraria - Novartis/Ipsen
Research Funding - Ipsen
Travel, Accommodations, Expenses - Novartis/Ipsen
 
Martina Ferrata
No Relationships to Disclose
 
Sebastian Krug
Travel, Accommodations, Expenses - Novartis/Ipsen
 
Patrick Michl
Honoraria - Baxalta; Falk Foundation; Lilly; MCI Group; Novartis/Ipsen
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly
Research Funding - Ipsen
 
Arno Schad
No Relationships to Disclose
 
Wilfried Roth
No Relationships to Disclose
 
Dirk Jaeger
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CureVac; Definiens; Genmab; Roche
 
Peter R. Galle
Honoraria - Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; Sillajen; Sirtex Medical
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; MSD; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Lilly
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Matthias M. Weber
Honoraria - Merck KGaA; Novartis/Ipsen
Consulting or Advisory Role - Merck KGaA; Novartis/Ipsen; Pfizer
Speakers' Bureau - Novartis/Ipsen
Research Funding - Merck KGaA; Novartis/Ipsen
Travel, Accommodations, Expenses - Novartis/Ipsen; Pfizer